Aceragen - Crunchbase Company Profile & Funding

Q: Who invested in Aceragen?

Aceragen is funded by Novaquest Capital Management.

Q: When was the last funding round for Aceragen?

Aceragen closed its last funding round on obfuscated from a Private Equity round.

Q: How much funding has Aceragen raised to date?

Aceragen has raised obfuscated.

Overview

Aceragen

Total Funding

obfuscation

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Aceragen

CB Rank

84614

Aceragen is a developer of therapeutic treatments intended for rare and ultra-rare diseases.

Acquired by

Idera Pharmaceuticals

Founded

obfuscation

Private

Private Equity

Durham, North Carolina, United States

11-50

www.aceragen.com/

Biotechnology

Health Care

Medical

Pharmaceutical

Funding Rounds

Private Equity

OBF

obfuscation

Key People

John Taylor: Chief Executive Officer
Past Role: Synageva BioPharma, Vice President, Corporate Development
John Taylor: Co-Founder, President and CEO
Past Role: Synageva BioPharma, Vice President, Corporate Development

Details

Legal Name

Aceragen Inc.

Operating Status

Closed

Company Type

For Profit

Founders

John Taylor

About the Company

Aceragen is a developer of therapeutic treatments intended for rare and ultra-rare diseases.

Contact Email

info@aceragen.com

Predictions & Insights

Products & Services

ACG-801

An investigational enzyme replacement therapy using recombinant human acid ceramidase for treating Farber disease.

ACG-701 (Melioidosis)

An investigational oral antibiotic, sodium fusidate, for treating melioidosis, a life-threatening infectious disease.

Research & Development

Aceragen is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Private Equity Round - Aceragen	1	obfuscated obfuscation	Novaquest Capital Management	Private Equity
obfuscated obfuscation	Private Equity Round - Aceragen	1	obfuscated obfuscation	Novaquest Capital Management	Private Equity
obfuscated obfuscation	Private Equity Round - Aceragen	1	obfuscated obfuscation	Novaquest Capital Management	Private Equity
obfuscated obfuscation	Private Equity Round - Aceragen	1	obfuscated obfuscation	Novaquest Capital Management	Private Equity
obfuscated obfuscation	Private Equity Round - Aceragen	1	obfuscated obfuscation	Novaquest Capital Management	Private Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Private Equity Round - Aceragen	1	obfuscated obfuscation	Novaquest Capital Management	Private Equity
obfuscated obfuscation	Private Equity Round - Aceragen	1	obfuscated obfuscation	Novaquest Capital Management	Private Equity
obfuscated obfuscation	Private Equity Round - Aceragen	1	obfuscated obfuscation	Novaquest Capital Management	Private Equity
obfuscated obfuscation	Private Equity Round - Aceragen	1	obfuscated obfuscation	Novaquest Capital Management	Private Equity
obfuscated obfuscation	Private Equity Round - Aceragen	1	obfuscated obfuscation	Novaquest Capital Management	Private Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Novaquest Capital Management	Yes	Private Equity Round - Aceragen	Ron Wooten, Stephen Lesser
Novaquest Capital Management	Yes	Private Equity Round - Aceragen	Ron Wooten, Stephen Lesser
Novaquest Capital Management	Yes	Private Equity Round - Aceragen	Ron Wooten, Stephen Lesser
Novaquest Capital Management	Yes	Private Equity Round - Aceragen	Ron Wooten, Stephen Lesser
Novaquest Capital Management	Yes	Private Equity Round - Aceragen	Ron Wooten, Stephen Lesser